Investment Rating - The report maintains a "Buy" rating for Kunming Pharmaceutical Group [2] Core Views - The company achieved a revenue of 8.401 billion yuan in 2024, a slight decrease of 0.34% year-on-year, while net profit attributable to shareholders increased by 19.86% to 648 million yuan [6] - The acquisition of Huaren Shenghuo is expected to enhance profitability and support the strategic integration of the company's Sanqi business [6] - The stable landing of centralized procurement is anticipated to lead to a recovery in product prices, providing a favorable outlook for future earnings [6] Financial Performance - In Q4 2024, the company reported a revenue of 2.601 billion yuan and a net profit of 203 million yuan [6] - The company plans to distribute a dividend of 3 yuan per ten shares, resulting in a payout ratio of 35.04% [6] - The company’s core products, including "Kun Traditional Chinese Medicine 1381," have shown significant growth, with combined revenue from key products increasing by 20% [6] Strategic Developments - The integration of Huaren Shenghuo into the company’s financials is expected to bolster profits and establish a benchmark in the Sanqi industry chain [6] - The company is focusing on brand building and channel development, which are progressing steadily [6] - The centralized procurement renewal in December 2024 has stabilized prices for key products, ensuring a stable revenue stream until December 31, 2027 [6] Earnings Forecast - The projected profits for 2025, 2026, and 2027 are estimated at 750 million yuan, 910 million yuan, and 1.135 billion yuan respectively [6] - The price-to-earnings ratio (PE) is expected to be 18, 15, and 12 times for the years 2025, 2026, and 2027 respectively [6]

[Table_Main] 证券研究报告 | 公司点评 昆药集团(600422.SH) 2025 年 03 月 12 日 买入（维持） 所属行业：医药生物/中药Ⅱ 当前价格(元)：17.77 证券分析师 周新明 资格编号：S0120524060001 邮箱：zhouxm＠tebon.com.cn 向潇 市场表现 -43% -29% -14% 0% 14% 29% 2024-03 2024-07 2024-11 昆药集团 沪深300 | 沪深300对比 | 1M | 2M | 3M | | --- | --- | --- | --- | | 绝对涨幅(%) | -0.45 | 13.91 | 12.18 | | 相对涨幅(%) | -1.95 | 8.31 | 13.37 | | 资料来源：德邦研究所，聚源数据 | | | | 相关研究 1.《昆药集团：集采续约平稳落地，圣 火并表未来可期》，2025.1.3 2.《昆药集团 2024 年中报点评：针剂 拖累表观业绩，口服核心品种表现亮 眼。》，2024.8.26 昆药集团 2024 年报点评：核心品种快 速增长，品牌+渠道建设稳步推进 投资要点 风险提示：品牌打 ...

证券分析师 王华炳 [Table_Main] 证券研究报告 | 公司点评 宝丰能源(600989.SH) 2025 年 03 月 12 日 买入（维持） 所属行业：基础化工/化学原料 当前价格(元)：17.43 资格编号：S0120524100001 邮箱：wanghb3＠tebon.com.cn 市场表现 -17% -9% 0% 9% 17% 26% 2024-03 2024-07 2024-11 2025-03 宝丰能源 沪深300 | 沪深300对比 | 1M | 2M | 3M | | --- | --- | --- | --- | | 绝对涨幅(%) | 5.51 | 5.32 | 5.64 | | 相对涨幅(%) | 4.47 | -0.28 | 6.99 | | 资料来源：德邦研究所，聚源数据 | | | | 相关研究 1.《宝丰能源(600989.SH)：进入产能 高速释放阶段！》，2024.12.26 2.《宝丰能源(600989.SH)：煤制烯烃 民企典范，成本领先成长广阔》， 2024.11.19 宝丰能源(600989.SH):价差修复 产能释放，看好公司长期成长！ 投资要点 请务必阅 ...

[Table_Main] 证券研究报告 | 公司点评 资格编号：S0120523070003 邮箱：gaojq＠tebon.com.cn 研究助理 市场表现 -17% -9% 0% 9% 17% 26% 34% 2024-03 2024-07 2024-11 2025-03 金徽股份 沪深300 | 沪深300对比 | 1M | 2M | 3M | | --- | --- | --- | --- | | 绝对涨幅(%) | 4.37 | 8.24 | 0.08 | | 相对涨幅(%) | 3.33 | 2.64 | 1.44 | | 资料来源：德邦研究所，聚源数据 | | | | 增持（维持） 所属行业：有色金属/工业金属 当前价格(元)：11.95 证券分析师 翟堃 资格编号：s0120523050002 邮箱：zhaikun＠tebon.com.cn 高嘉麒 相关研究 1.《金徽股份（603132.SH）：24H1 铅 锌矿量价齐升，净利增超 40%》， 2024.8.17 2.《金徽股份（603132.SH）：矿业权 出让收益金调整致净利同比下降，江 洛矿区整合进行时》，2024.3.25 金徽股份：行 ...

翟堃 资格编号：s0120523050002 邮箱：zhaikun＠tebon.com.cn 高嘉麒 [Table_Main] 证券研究报告 | 公司点评 增持（维持） 所属行业：有色金属/工业金属 当前价格(元)：11.95 证券分析师 资格编号：S0120523070003 邮箱：gaojq＠tebon.com.cn 研究助理 市场表现 -17% -9% 0% 9% 17% 26% 34% 2024-03 2024-07 2024-11 2025-03 金徽股份 沪深300 | 沪深300对比 | 1M | 2M | 3M | | --- | --- | --- | --- | | 绝对涨幅(%) | 4.37 | 8.24 | 0.08 | | 相对涨幅(%) | 3.33 | 2.64 | 1.44 | | 资料来源：德邦研究所，聚源数据 | | | | 相关研究 1.《金徽股份（603132.SH）：24H1 铅 锌矿量价齐升，净利增超 40%》， 2024.8.17 2.《金徽股份（603132.SH）：矿业权 出让收益金调整致净利同比下降，江 洛矿区整合进行时》，2024.3.25 金徽股份：行 ...

[Table_Main] 证券研究报告 | 行业点评 有色金属 优于大市（维持） 市场表现 -18% -12% -6% 0% 6% 12% 18% 24% 2024-03 2024-07 2024-11 有色金属 沪深300 资料来源：聚源数据，德邦研究所 相关研究 1.《有色金属周报：特朗普确认对加 墨征收关税后暂缓执行，通胀预期驱 动 金 属 价 格 进 入 上 涨 通 道 》， 2025.3.9 2.《有色金属周报：俄罗斯提出与乌 克兰停战要求，战后重建或拉动工业 金属需求》，2025.3.1 3.《有色金属周报：关税阴影笼罩， 黄金长线仍为主线》，2025.2.23 证券分析师 翟堃 资格编号：s0120523050002 邮箱：zhaikun＠tebon.com.cn 高嘉麒 资格编号：S0120523070003 邮箱：gaojq＠tebon.com.cn 研究助理 4.《俄乌和谈启动，重建有望拉动铜 铝钢需求》，2025.2.20 5.《有色金属周报：美宣布对进口钢 铁和铝征收 25%的关税，黄金价格 上涨》，2025.2.15 电解铝：盈利快速扩张，景气度 有望持续 [Table_Summar ...

Investment Rating - The report upgrades the investment rating for the food and beverage industry to "Outperform the Market" [2] Core Viewpoints - The report highlights a recovery in real estate data, suggesting that the industry fundamentals are expected to improve gradually. The white liquor sector shows potential for investment opportunities in 2025, with recommendations for leading companies with strong performance certainty and channel control capabilities [5][8] - The beer sector is under short-term pressure but maintains a structural upgrade trend, with expectations for demand recovery to drive performance improvements [9] - The report emphasizes the importance of policy support in boosting consumer demand across various segments, including the restaurant supply chain and snack foods, which are expected to benefit from ongoing channel reforms [11][13] Summary by Sections 1. Weekly Insights - The white liquor sector has shown a 1.53% increase, outperforming the CSI 300 index by 0.14%, with leading stocks like Yingjia Gongjiu and Jiansi Yuan showing significant gains [5][8] 2. Market Performance - The food and beverage sector underperformed the CSI 300 index by 0.65 percentage points, with a 0.74% increase over the week compared to a 1.39% increase in the CSI 300 [16] 3. Key Data Tracking - White liquor prices have shown fluctuations, with the price of Feitian Moutai at 2450 RMB per bottle, down 2.00% from the previous week [30] - The beer production volume for December 2024 was 241.10 million liters, reflecting a year-on-year increase of 12.20% [33] - The average price of fresh milk was 3.09 RMB per kilogram, showing a slight decrease of 0.32% [37] 4. Company Recommendations - Recommended stocks in the white liquor sector include Kweichow Moutai, Wuliangye, and Luzhou Laojiao. In the beer sector, Qingdao Beer and Chongqing Beer are highlighted, while East Peak Beverage and Nongfu Spring are recommended in the soft drink segment [14]

Investment Rating - The report maintains an "Outperform" rating for the basic chemical industry [2] Core Insights - The supply expansion cycle for the industry has come to a close, with unprecedented cooperation among major players to stabilize prices. The total production capacity of the industry has increased significantly from 12,800 tons in 2019 to 34,800 tons in 2024, leading to a situation where supply exceeds demand. However, regulatory constraints on new capacity due to environmental concerns are expected to ease the oversupply pressure [7][13][19] - Demand for sucralose is accelerating as it replaces artificial sweeteners that have been flagged for health concerns. The domestic consumption of sucralose has grown at a CAGR of 20.3% from 2019 to 2023, while global artificial sweetener consumption has only grown at 4.0% during the same period. The beverage sector is projected to see a 4.9% increase in production in 2024, further supporting demand [7][32][35] - A tight balance between supply and demand is expected to continue, providing significant earnings elasticity for companies in the industry. If sucralose can replace 20% of the first to third generation artificial sweeteners by 2026, the total market space could reach 26,517 tons. The industry is projected to have a supply-demand gap of -223 tons in 2025 and 148 tons in 2026 [7][52] Summary by Sections Supply Dynamics - The expansion cycle for sucralose production has concluded, with a significant increase in market concentration. The CR3 ratio has risen from 74.22% in 2019 to 83.33% in 2024, indicating a more orderly competitive environment [7][13][19] - Major companies have begun to implement production cuts to manage inventory, resulting in a total production of 19,928 tons in 2024, down 8.34% from 2023 [7][19][24] Demand Trends - Sucralose is positioned to replace potentially harmful sweeteners, with a projected market space of 41,773 tons by 2032 if it can replace 60% of the first to third generation sweeteners. The domestic consumption of sucralose has shown a stable growth trend, with a 13.04% CAGR from 2019 to 2023 [32][35][34] - The beverage industry is expected to drive demand, with a significant increase in production anticipated in the upcoming summer season [35][36] Market Outlook - The report anticipates that the supply-demand balance will remain tight, with limited new capacity expected in the near future. The industry is projected to maintain a supply-demand gap of -223 tons in 2025 and 148 tons in 2026, indicating a stable market environment [52][7] - The report highlights the potential for price increases, with significant earnings sensitivity for companies like Jinhe Industrial, which could see substantial revenue increases with price hikes [7][52]

Investment Rating - The report maintains an "Outperform" rating for the pharmaceutical and biotechnology sector [2] Core Views - The report highlights strong growth expectations for several companies in the pharmaceutical sector, particularly in innovative drugs and specific sub-industries such as packaging and vitamins [5][12][13][21][25][30][37] Summary by Sections 1. Companies with Positive Q1 Performance Expectations - **Linuo Packaging**: The company is positioned well in the borosilicate molded bottle industry, with rapid expansion expected to enhance performance. The market demand for molded bottles is projected to reach 74 billion units by 2027, while current production capacity is only about 54 billion units [12] - **Zhejiang Medicine**: Anticipated high growth in Q1 2025 due to strong overseas demand for vitamins A and E, with vitamin E prices showing a significant increase [13][17] - **Huayuan Bio**: Expected to exceed Q1 performance expectations, driven by high prices for vitamin D3 and the rollout of new projects [21][24] - **Yimaitong**: As China's largest online professional physician platform, it has a solid user base and is leveraging AI to enhance its services [25][29] - **Gushengtang**: The company is integrating AI with traditional Chinese medicine, showing a steady increase in patient visits and average spending per visit [30][36] - **Innovative Drugs**: Focus on the volume of products entering the medical insurance list in Q1 2025, with several key drugs expected to perform well [37] 2. Market Performance Overview - The pharmaceutical sector index rose by 1.06% from March 3 to March 7, 2025, underperforming the CSI 300 index by 0.32%. Year-to-date, the sector index has increased by 2.19%, outperforming the CSI 300 by 1.95% [39][41] 3. Sector Valuation and Trading Volume - As of March 7, 2025, the overall valuation of the pharmaceutical sector is 31.2, reflecting a slight increase from the previous week [46] - The total trading volume for the pharmaceutical sector was 353.32 billion yuan, accounting for 4.2% of the total A-share market volume, with a decrease of 13.9% compared to the previous trading period [50][52]

Investment Rating - The report maintains an "Outperform" rating for the electrical equipment industry [2]. Core Insights - The report highlights stable prices for silicon materials and an increase in photovoltaic glass prices driven by policy changes and demand surges [5][11]. - It suggests investment opportunities in various segments of the renewable energy sector, including solar, wind, and electric vehicles [5][6]. Summary by Sections Silicon Material and Photovoltaic Glass - Silicon material prices remain stable, with N-type polysilicon trading between 39,000-46,000 CNY/ton and an average price of 41,700 CNY/ton. P-type polysilicon averages 34,000 CNY/ton [11][12]. - Photovoltaic glass prices have increased, with 2.0mm glass averaging 13.50 CNY/sqm (up 1 CNY from February) and 3.2mm glass at 22.50 CNY/sqm (up 2 CNY) [11][12]. Investment Recommendations in Renewable Energy - Suggested focus areas include: 1. Integrated component companies with new battery technologies: JinkoSolar, LONGi Green Energy, JA Solar, Trina Solar [5][14]. 2. Emerging technologies in the battery segment: Tongwei Co., Aiko Solar, Junda Co. [5][14]. 3. Silicon wafer companies with efficiency or volume growth potential: TCL Zhonghuan, Shuangliang Eco-Energy [5][14]. 4. Leading inverter companies benefiting from overall growth: Sungrow Power Supply, GoodWe [5][14]. 5. Energy storage battery suppliers: CATL, EVE Energy, Pylontech [5][14]. Wind Power Sector - Recommended stocks include: 1. Offshore wind-related companies: Qifan Cable, Haizhuang Wind Power, Zhenjiang Co. [5][14]. 2. Upstream component manufacturers: Guoda Special Materials, Lixing Co. [5][14]. 3. Turbine manufacturers: Sany Heavy Energy, Mingyang Smart Energy [5][14]. Electric Vehicle Sector - Investment suggestions focus on: 1. Leading companies with global competitiveness: CATL, Enjie, BTR, Tianneng Battery, and others [5][6]. 2. Second-tier lithium battery companies: EVE Energy, Guoxuan High-Tech, and others [5][6]. 3. Quality companies in lithium battery materials: Zhongke Electric, Dangsheng Technology, and others [5][6]. 4. Leading component manufacturers benefiting from global electrification: Inovance Technology, Sanhua Intelligent Controls, and others [5][6].